Is eculizumab used off-label for any other conditions?

Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study Apr 7, 2025 ... ... Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris ® in the U.S. Teva and Samsung Bioepis entered into ... Mar 18, 2025 ... How is Soliris administered in myasthenia gravis? · 900 mg weekly for the first four weeks · 1,200 mg in the fifth week · 1,200 mg every other ... Nov 24, 2020 ... Soliris is not intended for acute treatment of a NMOSD relapse. Route of administration: Intravenous (IV) infusion. Dosage: Patients must be ... Apr 10, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., Boston, MA, USA) ... Soliris (eculizumab) [prescribing information]. Boston, MA ... Feb 15, 2025 ... You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with eculizumab to decrease the risk that you ... Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug eculizumab (Soliris) using ready-made anti-idiotypic antibodies. Jan 23, 2024 ... This trial was a phase 3, patient-blinded, randomized control study assessing the impact of eculizumab on the course of acute renal failure in patients with ... NMOSD patients receiving Soliris should be monitored for early signs of meningococcal infection. No ongoing monitoring is recommended following discontinuation ... In this way Soliris improves anaemia, tiredness, and other signs and symptoms of PNH. Patients with aHUS have an inflammatory condition which affects the blood ...